Merganser Biotech focuses on the evaluation of novel hepcidin mimetic peptides for the treatment of beta thalassemia and other rare hematological and iron overload diseases. The company obtained an exclusive worldwide license to patent rights for this technology from the Regents of the University of California in 2013.
Market
Hematological and iron overload diseases
Location
Newtown Square,
PA,
USA
Coinvestors
BioAdvance, Frazier Healthcare, Novartis Venture Funds, Osage University Partners, Stateside Developments, Sutter Hill Ventures